Although efficacy was low, subsequent development of CSP using a particle-based approach has led to the currently most advanced malaria sub-unit vaccine, RTS,S/AS01, that elicits 30 % protection in young children [30] primarily mediated by anti-CSP antibodies and CD4+ T cells [31, 32]. The gene discussed is CD4; the disease is malaria.